These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9103145)

  • 21. [Interferon-alpha therapy in chronic myelogenous leukemia].
    Ohnishi K
    Rinsho Ketsueki; 2000 Apr; 41(4):275-9. PubMed ID: 10846454
    [No Abstract]   [Full Text] [Related]  

  • 22. Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients.
    Rachmani R; Avigdor A; Youkla M; Raanani P; Zilber M; Ravid M; Ben-Bassat I
    Acta Haematol; 1998; 100(4):204-6. PubMed ID: 9973644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of hyperthyroidism during long term interferon therapy in a patient with chronic myelogenous leukemia: case report.
    Ozet A; Ozet G; Calişkaner Z; Kömürcü S; Oztürk B
    Endocr J; 1997 Oct; 44(5):715-7. PubMed ID: 9466328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Interferon-alpha in the treatment of chronic myeloid leukemia].
    Guilhot F
    Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394
    [No Abstract]   [Full Text] [Related]  

  • 25. Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy.
    Kuroiwa M; Gondo H; Ashida K; Kamimura T; Miyamoto T; Niho Y; Tsukimori K; Nakano H; Ohga S
    Am J Hematol; 1998 Sep; 59(1):101-2. PubMed ID: 9723590
    [No Abstract]   [Full Text] [Related]  

  • 26. Alpha-interferon in chronic myelogenous leukaemia.
    Kumar L; Gulati SC
    Lancet; 1995 Oct; 346(8981):984-6. PubMed ID: 7475589
    [No Abstract]   [Full Text] [Related]  

  • 27. Does interferon-a exert an anti-leukemic effect by enhancing cell mediated immunity in chronic myeloid leukemia?
    Muretto P; Tomassoni S; Staccioli MP; Tabellini L; D'Adamo F; Delfini C
    Haematologica; 2000 Feb; 85(2):212-3. PubMed ID: 10681734
    [No Abstract]   [Full Text] [Related]  

  • 28. Renal thrombotic microangiopathy induced by interferon-alpha.
    Badid C; McGregor B; Faivre JM; Guerard A; Juillard L; Fouque D; Laville M
    Nephrol Dial Transplant; 2001 Apr; 16(4):846-8. PubMed ID: 11274286
    [No Abstract]   [Full Text] [Related]  

  • 29. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
    Peggs K; Mackinnon S
    N Engl J Med; 2003 Mar; 348(11):1048-50. PubMed ID: 12637616
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies.
    Messori A
    Ann Oncol; 1998 Apr; 9(4):389-96. PubMed ID: 9636829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease in chronic myeloid leukemia.
    Löwenberg B
    N Engl J Med; 2003 Oct; 349(15):1399-401. PubMed ID: 14534331
    [No Abstract]   [Full Text] [Related]  

  • 32. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
    Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
    Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preliminary results of interferon alpha treatment for patients with chronic myelogenous leukemia].
    Popławska-Szczygłowska L; Starzyńska J; Chmarzyńska-Mróz E
    Pol Tyg Lek; 1996 May; 51(19-22):283-4. PubMed ID: 9289711
    [No Abstract]   [Full Text] [Related]  

  • 37. ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML).
    Simonsson B; Kloke O; Stahel RA;
    Ann Oncol; 2005; 16 Suppl 1():i52-3. PubMed ID: 15888754
    [No Abstract]   [Full Text] [Related]  

  • 38. [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia].
    López Hernández MA; Flores-Chapa JD; Trueba Christy E; Borbolla Escoboza JR; Carrillo Rosales T
    Rev Invest Clin; 1996; 48(4):281-7. PubMed ID: 8966391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Not so NICE for CML.
    Goldman J; Apperley J; Clark R; Green T; Holyoake T; O'Brien S; Shepherd P
    Lancet; 2002 Jun; 359(9322):2036. PubMed ID: 12076575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.